Roundview Capital LLC Sells 3,253 Shares of Danaher Corporation (NYSE:DHR)

Roundview Capital LLC lessened its stake in Danaher Corporation (NYSE:DHR - Free Report) by 8.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,700 shares of the conglomerate's stock after selling 3,253 shares during the period. Roundview Capital LLC's holdings in Danaher were worth $6,908,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of DHR. Geode Capital Management LLC lifted its stake in Danaher by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock valued at $3,056,996,000 after buying an additional 315,446 shares in the last quarter. Norges Bank purchased a new stake in Danaher during the fourth quarter valued at about $2,130,740,000. Bank of New York Mellon Corp lifted its position in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares in the last quarter. Northern Trust Corp lifted its position in shares of Danaher by 14.3% in the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after purchasing an additional 992,594 shares in the last quarter. Finally, Capital World Investors lifted its position in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. Robert W. Baird increased their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. TD Cowen raised their price objective on shares of Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Wolfe Research cut their price objective on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research report on Monday, April 7th. Finally, UBS Group cut their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Stock Up 1.4%

Shares of DHR traded up $2.79 on Friday, hitting $205.60. The company's stock had a trading volume of 5,355,676 shares, compared to its average volume of 3,965,185. The firm has a market capitalization of $147.22 billion, a price-to-earnings ratio of 43.74, a P/E/G ratio of 2.82 and a beta of 0.77. The firm's fifty day moving average price is $196.38 and its 200-day moving average price is $203.92. The company has a quick ratio of 1.05, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the previous year, the business posted $1.72 EPS. The business's quarterly revenue was up 3.4% compared to the same quarter last year. On average, equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 25th. Stockholders of record on Friday, June 27th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.